Stoke Therapeutics STOK
NASDAQ STOK
$29.58 -0.41 (-1.38%)
As of: Sep 4, 2026 · 12:48 PM EDT

Stoke Therapeutics (STOK) Non Operating Interest Expenses (2025 - 2026)

Analysis

Stoke Therapeutics (STOK) Non Operating Interest Expenses (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Stoke Therapeutics 1.95 Bn 1.66 Bn - 17,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 17,000.00
Mar 31, 2026 23,000.00
Jun 30, 2025 3,000.00
Mar 31, 2025 1,000.00